InMed Pharmaceuticals Files 8-K: Officer/Director Changes & Financials

Ticker: INM · Form: 8-K · Filed: Oct 16, 2025 · CIK: 1728328

Sentiment: neutral

Topics: corporate-governance, officer-changes, financials

TL;DR

InMed Pharma 8-K: Leadership changes, officer appointments, and financial updates filed.

AI Summary

InMed Pharmaceuticals Inc. filed an 8-K on October 16, 2025, reporting events as of October 14, 2025. The filing indicates changes related to the departure of directors or officers, the election of directors, the appointment of certain officers, and compensatory arrangements. It also includes Regulation FD disclosures and financial statements/exhibits.

Why It Matters

This filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational execution.

Risk Assessment

Risk Level: medium — Changes in directors or officers can indicate internal shifts that may affect company strategy or stability.

Key Players & Entities

FAQ

What specific changes occurred regarding directors or officers?

The filing indicates "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers" as an item of information, but the specific details of these changes are not provided in the provided text snippet.

Are there any new compensatory arrangements for officers mentioned?

The filing lists "Compensatory Arrangements of Certain Officers" as an item of information, suggesting such arrangements may be detailed within the full report.

What is the significance of the Regulation FD Disclosure?

A Regulation FD Disclosure item indicates that the company is providing material non-public information to the public in compliance with fair disclosure rules.

What types of financial statements or exhibits are included?

The filing lists "Financial Statements and Exhibits" as an item, implying that financial information and supporting documents are part of the report.

When was InMed Pharmaceuticals Inc. incorporated and in which jurisdiction?

InMed Pharmaceuticals Inc. was incorporated in British Columbia, Canada.

Filing Stats: 887 words · 4 min read · ~3 pages · Grade level 10 · Accepted 2025-10-16 16:01:12

Filing Documents

02 Departure of Directors or Certain

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Mr. John Bathery On October 14, 2025, the board of directors (the "Board") of InMed Pharmaceuticals Inc. (the "Company") appointed Mr. John Bathery as a director and concurrently increased the size of the Board to six members, effective as of October 14, 2025. Mr. Bathery may be appointed to one or more of the committees of the Board, but the appointments have not been determined at this time. Mr. Bathery's term as a member of the Board will expire immediately before the Annual General Meeting to be held in 2025. There are no arrangements nor understandings between Mr. Bathery, on the one hand, and the Company or any other persons, on the other hand, pursuant to which he was selected as a director of the Company. There are no related party transactions between the Company and Mr. Bathery (or any of his immediate family members) requiring disclosure under Item 404(a) of Regulation S-K. Mr. Bathery does not have any family relationship with any of the Company's other directors or executive officers. Mr. Bathery will be entitled to receive compensation for service as a non-employee director consistent with the Company's non-employee director compensation program, which includes an annual retainer of US50,000 and may include additional amounts for serving as a Board committee member, if applicable. In connection with his appointment to the Board, Mr. Bathery executed the Company's standard form of indemnification agreement for directors. Retirement of Mr. Bryan Baldasare On October 15, 2025, Mr. Bryan Baldasare notified the Company that he will not stand for re-election at the Company's 2025 Annual General Meeting due to increasing professional obligations. There is no disagreement between Mr. Baldasare and the Company, as defined in 17 CFR 240.3b-7, on any matter relating to the Company's op

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 16, 2025, the Company issued a press release announcing the appointment of Mr. John Bathery as a director and Mr. Bryan Baldasare notified the Company that he will not stand for re-election at the Company's 2025 Annual General Meeting. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The information set forth in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press Release filed October 16, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: October 16, 2025 By: /s/ Eric A. Adams Eric A. Adams President and CEO 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing